| Year |
Citation |
Score |
| 2023 |
Yu G, Corn PG, Mak CSL, Liang X, Zhang M, Troncoso P, Song JH, Lin SC, Song X, Liu J, Zhang J, Logothetis CJ, Melancon MP, Panaretakis T, Wang G, ... Lin SH, et al. Prostate cancer-induced endothelial-to-osteoblast transition generates an immunosuppressive bone tumor microenvironment. Biorxiv : the Preprint Server For Biology. PMID 38076845 DOI: 10.1101/2023.11.30.569496 |
0.303 |
|
| 2023 |
Gentile E, Hahn AW, Song JH, Hoang A, Shepherd PDA, Ramachandran S, Navone NM, Efstathiou E, Titus M, Corn PG, Lin SH, Logothetis CJ, Panaretakis T. Monitoring Glucocorticoid Receptor in plasma derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Research Communications. PMID 37930121 DOI: 10.1158/2767-9764.CRC-23-0362 |
0.416 |
|
| 2023 |
Vardaki I, Özcan SS, Fonseca P, Lin SH, Logothetis CJ, Yachnin J, Ullen A, Panaretakis T. Transcriptomic analysis of plasma exosomes provides molecular information of response to cabazitaxel treatment in men with metastatic castration-resistant prostate cancer. The Prostate. PMID 37074030 DOI: 10.1002/pros.24536 |
0.444 |
|
| 2023 |
Damasco JA, Yu G, Kumar A, Perez J, Lirag RCM, Whitley EM, Lin SH, Melancon MP. Alendronate conjugate for targeted delivery to bone-forming prostate cancer. Talanta. 256: 124308. PMID 36774896 DOI: 10.1016/j.talanta.2023.124308 |
0.302 |
|
| 2022 |
Sakellakis MJ, Hahn AW, Ramachandran S, Zhang M, Hoang A, Song JH, Liu J, Wang F, Basu HS, Sheperd P, Wang X, Frigo DE, Lin SH, Panaretakis T, Zhang J, et al. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. Prostate Cancer and Prostatic Diseases. PMID 36100698 DOI: 10.1038/s41391-022-00590-x |
0.508 |
|
| 2021 |
Lee YC, Lin SC, Yu G, Zhu M, Song JH, Rivera K, Pappin DJ, Logothetis CJ, Panaretakis T, Wang G, Yu-Lee LY, Lin SH. Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition. Oncogene. PMID 34845375 DOI: 10.1038/s41388-021-02131-7 |
0.447 |
|
| 2021 |
Zhu M, Peng R, Liang X, Lan Z, Tang M, Hou P, Song JH, Mak CSL, Park J, Zheng SE, Huang A, Ma X, Chen R, Chang Q, Logothetis CJ, ... ... Lin SH, et al. P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis. Oncogene. PMID 34471235 DOI: 10.1038/s41388-021-02000-3 |
0.548 |
|
| 2021 |
Pan T, Lin SC, Lee YC, Yu G, Song JH, Pan J, Titus M, Satcher RL, Panaretakis T, Logothetis C, Yu-Lee LY, Lin SH. Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone. Oncogene. PMID 34127814 DOI: 10.1038/s41388-021-01874-7 |
0.34 |
|
| 2021 |
Yu G, Shen P, Lee YC, Pan J, Song JH, Pan T, Lin SC, Liang X, Wang G, Panaretakis T, Logothetis CJ, Gallick GE, Yu-Lee LY, Lin SH. Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4. Iscience. 24: 102388. PMID 33981975 DOI: 10.1016/j.isci.2021.102388 |
0.5 |
|
| 2021 |
Rojo RD, Perez JVD, Damasco JA, Yu G, Lin SC, Heralde FM, Novone NM, Santos EB, Lin SH, Melancon MP. Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice. International Journal of Hyperthermia : the Official Journal of European Society For Hyperthermic Oncology, North American Hyperthermia Group. 38: 650-662. PMID 33882773 DOI: 10.1080/02656736.2021.1914873 |
0.465 |
|
| 2021 |
Vardaki I, Corn P, Gentile E, Song JH, Madan N, Hoang A, Parikh NU, Guerra LD, Lee YC, Lin SC, Yu G, Santos E, Melancon M, Troncoso P, Navone NM, ... ... Lin SH, et al. Radium 223 treatment increase immune checkpoint expression in extracellular vesicles from the metastatic prostate cancer bone microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33753455 DOI: 10.1158/1078-0432.CCR-20-4790 |
0.401 |
|
| 2020 |
Koinis F, Corn P, Parikh N, Song J, Vardaki I, Mourkioti I, Lin SH, Logothetis C, Panaretakis T, Gallick G. Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer. Cancers. 12. PMID 31963871 DOI: 10.3390/Cancers12010244 |
0.368 |
|
| 2020 |
Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, et al. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31941830 DOI: 10.1158/1078-0432.Ccr-19-2389 |
0.491 |
|
| 2019 |
Yu-Lee LY, Lee YC, Pan J, Lin SC, Pan T, Yu G, Hawke DH, Pan BF, Lin SH. Bone secreted factors induce cellular quiescence in prostate cancer cells. Scientific Reports. 9: 18635. PMID 31819067 DOI: 10.1038/s41598-019-54566-4 |
0.399 |
|
| 2018 |
Lin SC, Yu-Lee LY, Lin SH. Osteoblastic Factors in Prostate Cancer Bone Metastasis. Current Osteoporosis Reports. PMID 30203251 DOI: 10.1007/s11914-018-0480-6 |
0.353 |
|
| 2018 |
Yu G, Cheng CJ, Lin SC, Lee YC, Frigo DE, Yu-Lee LY, Gallick GE, Titus MA, Nutt LK, Lin SH. Organelle-derived acetyl-CoA promotes prostate cancer cell survival, migration, and metastasis via activation of calmodulin kinase II. Cancer Research. PMID 29535221 DOI: 10.1158/0008-5472.Can-17-2392 |
0.471 |
|
| 2018 |
Yu-Lee LY, Yu G, Lee YC, Lin SC, Pan J, Pan T, Yu KJ, Liu B, Creighton CJ, Rodriguez-Canales J, Villalobos PA, Wistuba II, de Nadal E, Posas F, Gallick GE, ... Lin SH, et al. Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFβRIII-p38MAPK-pS249/T252RB pathway. Cancer Research. PMID 29514796 DOI: 10.1158/0008-5472.Can-17-1051 |
0.419 |
|
| 2017 |
Yu KJ, Li JK, Lee YC, Yu G, Lin SC, Pan T, Satcher RL, Titus MA, Yu-Lee LY, Weng WH, Gallick GE, Lin SH. Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone. Oncotarget. 8: 74987-75006. PMID 29088840 DOI: 10.18632/oncotarget.20489 |
0.403 |
|
| 2017 |
Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemotherapy and Pharmacology. PMID 28730293 DOI: 10.1007/S00280-017-3391-9 |
0.384 |
|
| 2017 |
Lin SC, Lee YC, Yu G, Cheng CJ, Zhou X, Chu K, Murshed M, Le NT, Baseler L, Abe JI, Fujiwara K, deCrombrugghe B, Logothetis CJ, Gallick GE, Yu-Lee LY, ... ... Lin SH, et al. Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Developmental Cell. 41: 467-480.e3. PMID 28586644 DOI: 10.1016/J.Devcel.2017.05.005 |
0.314 |
|
| 2017 |
Shen P, Zeng H, Ortiz A, Cheng C, Lee Y, Yu G, Lin S, Yu-Lee L, Lin S. Angiomotin to regulate prostate cancer cell proliferation by signaling through Hippo-YAP pathway. Journal of Clinical Oncology. 35: e559-e559. DOI: 10.1200/JCO.2017.35.6_SUPPL.E559 |
0.513 |
|
| 2017 |
Shen P, Zeng H, Ortiz A, Cheng C, Lee Y, Yu G, Lin S, Yu-Lee L, Lin S. MP99-11 ANGIOMOTIN REGULATES PROSTATE CANCER CELL PROLIFERATION BY SIGNALING THROUGH HIPPO-YAP PATHWAY Journal of Urology. 197. DOI: 10.1016/j.juro.2017.02.3097 |
0.532 |
|
| 2016 |
Zeng H, Ortiz A, Shen PF, Cheng CJ, Lee YC, Yu G, Lin SC, Creighton CJ, Yu-Lee LY, Lin SH. Angiomotin regulates prostate cancer cell proliferation by signaling through the Hippo-YAP pathway. Oncotarget. PMID 28052036 DOI: 10.18632/Oncotarget.14358 |
0.546 |
|
| 2015 |
Lee YC, Lin SC, Yu G, Cheng CJ, Liu B, Liu HC, Hawke DH, Parikh NU, Varkaris A, Corn P, Logothetis C, Satcher RL, Yu-Lee LY, Gallick GE, Lin SH. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Research. PMID 26530902 DOI: 10.1158/0008-5472.CAN-15-1215 |
0.415 |
|
| 2015 |
Satcher RL, Pan T, Bilen MA, Li X, Lee YC, Ortiz A, Kowalczyk AP, Yu-Lee LY, Lin SH. Cadherin-11 endocytosis through binding to clathrin promotes cadherin-11-mediated migration in prostate cancer cells. Journal of Cell Science. PMID 26519476 DOI: 10.1242/jcs.176081 |
0.508 |
|
| 2015 |
Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio AM, Hoang A, Gaur S, Thorpe L, Maity SN, Bar-Eli M, Czerniak BA, Shao Y, Alauddin M, ... Lin SH, et al. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR-2 as Targets for Growth Inhibition of Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26272062 DOI: 10.1158/1078-0432.Ccr-15-0235 |
0.411 |
|
| 2015 |
Chatterji T, Varkaris AS, Parikh NU, Song JH, Cheng CJ, Schweppe RE, Alexander S, Davis JW, Troncoso P, Friedl P, Kuang J, Lin SH, Gallick GE. Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells. Oncotarget. 6: 10175-94. PMID 25868388 DOI: 10.18632/Oncotarget.3391 |
0.34 |
|
| 2015 |
Bilen MA, Lin SH, Tang DG, Parikh K, Lee MH, Yeung SC, Tu SM. Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series. Case Reports in Oncological Medicine. 2015: 471861. PMID 25861496 DOI: 10.1155/2015/471861 |
0.43 |
|
| 2015 |
Mandelin J, Cardó-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, Logothetis CJ, Rietz AC, Dobroff AS, Proneth B, Sidman RL, Pasqualini R, Arap W. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proceedings of the National Academy of Sciences of the United States of America. 112: 3776-81. PMID 25762070 DOI: 10.1073/Pnas.1500128112 |
0.504 |
|
| 2015 |
Lee YC, Gajdosik MS, Josic D, Clifton JG, Logothetis C, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment. Molecular & Cellular Proteomics : McP. 14: 471-83. PMID 25527621 DOI: 10.1074/Mcp.M114.039909 |
0.38 |
|
| 2015 |
Ortiz A, Lee YC, Yu G, Liu HC, Lin SC, Bilen MA, Cho H, Yu-Lee LY, Lin SH. Angiomotin is a novel component of cadherin-11/β-catenin/p120 complex and is critical for cadherin-11-mediated cell migration. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 29: 1080-91. PMID 25466890 DOI: 10.1096/fj.14-261594 |
0.438 |
|
| 2015 |
Yu G, Lee YC, Cheng CJ, Wu CF, Song JH, Gallick GE, Yu-Lee LY, Kuang J, Lin SH. RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival. Molecular Cancer Research : McR. 13: 348-57. PMID 25189355 DOI: 10.1158/1541-7786.MCR-14-0384-T |
0.525 |
|
| 2015 |
Jin JK, Tien PC, Cheng CJ, Song JH, Huang C, Lin SH, Gallick GE. Talin1 phosphorylation activates β1 integrins: a novel mechanism to promote prostate cancer bone metastasis. Oncogene. 34: 1811-21. PMID 24793790 DOI: 10.1038/Onc.2014.116 |
0.368 |
|
| 2014 |
Bilen MA, Reyes A, Bhowmick D, Maa A, Bast R, Pisters LL, Lin SH, Logothetis CJ, Tu SM. Variant prostate carcinoma and elevated serum CA-125. The Canadian Journal of Urology. 21: 7442-8. PMID 25347368 |
0.388 |
|
| 2014 |
Mitani Y, Rao PH, Maity SN, Lee YC, Ferrarotto R, Post JC, Licitra L, Lippman SM, Kies MS, Weber RS, Caulin C, Lin SH, El-Naggar AK. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6570-81. PMID 25316813 DOI: 10.1158/1078-0432.Ccr-14-1746 |
0.42 |
|
| 2014 |
Bilen MA, Hess KR, Aparicio A, Kim J, Zurita AJ, Pagliaro LC, Araujo JC, Corn PG, Atkinson BJ, Tannir NM, Sharma P, Lin S, Logothetis C, Tu S. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 32: e16046-e16046. DOI: 10.1200/JCO.2014.32.15_SUPPL.E16046 |
0.399 |
|
| 2013 |
Sung SY, Liao CH, Wu HP, Hsiao WC, Wu IH, Jinpu, Yu, Lin SH, Hsieh CL. Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer. Plos One. 8: e71637. PMID 23977098 DOI: 10.1371/journal.pone.0071637 |
0.485 |
|
| 2013 |
Lee YC, Bilen MA, Yu G, Lin SC, Huang CF, Ortiz A, Cho H, Song JH, Satcher RL, Kuang J, Gallick GE, Yu-Lee LY, Huang W, Lin SH. Inhibition of cell adhesion by a cadherin-11 antibody thwarts bone metastasis. Molecular Cancer Research : McR. 11: 1401-11. PMID 23913163 DOI: 10.1158/1541-7786.MCR-13-0108 |
0.475 |
|
| 2013 |
Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discovery. 3: 849-61. PMID 23811619 DOI: 10.1158/2159-8290.Cd-12-0460 |
0.515 |
|
| 2013 |
Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, McIntyre BW, Logothetis CJ, Gallick GE, Lin SH. Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. Molecular Cancer Research : McR. 11: 405-17. PMID 23339185 DOI: 10.1158/1541-7786.Mcr-12-0551 |
0.502 |
|
| 2013 |
Deeraksa A, Pan J, Sha Y, Liu XD, Eissa NT, Lin SH, Yu-Lee LY. Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis. Oncogene. 32: 2973-83. PMID 22890325 DOI: 10.1038/onc.2012.309 |
0.398 |
|
| 2013 |
Satcher RL, Bamidele O, Lin P, Lin S, Moon B, Hernandez M, Lewis V, Chilton J. Racial Disparities in Survival Outcomes of Prostate Cancer Patients after Surgery for Bone Metastases Journal of Cancer Therapy. 4: 27-36. DOI: 10.4236/JCT.2013.44A004 |
0.364 |
|
| 2013 |
Zurita AJ, Bischoff FZ, Gorlov I, Mayer JA, Pircher TJ, Mikolajczyk S, Logothetis C, Lin S. Cadherin-11 (Cad11) for detection of epithelial-mesenchymal transition (EMT) in circulating prostate cancer (PCa) cells. Journal of Clinical Oncology. 31: e22047-e22047. DOI: 10.1200/jco.2013.31.15_suppl.e22047 |
0.373 |
|
| 2013 |
Sung S, Liao C, Hsiao W, Lin S, Hsieh C. 212 LOSS OF LET-7 MICRORNA EXPRESSION UPREGULATES IL-6 IN MESENCHYMAL STEM CELLS AND TRIGGERS REACTIVE STROMAL RESPONSES TO PROSTATE CANCER Journal of Urology. 189. DOI: 10.1016/J.JURO.2013.02.1592 |
0.447 |
|
| 2012 |
Tu SM, Lin SH. Prostate cancer stem cells. Clinical Genitourinary Cancer. 10: 69-76. PMID 22421313 DOI: 10.1016/j.clgc.2012.01.002 |
0.55 |
|
| 2012 |
Gallick GE, Corn PG, Zurita AJ, Lin SH. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Medicinal Chemistry. 4: 107-19. PMID 22168167 DOI: 10.4155/fmc.11.161 |
0.31 |
|
| 2012 |
Ye X, Lee YC, Choueiri M, Chu K, Huang CF, Tsai WW, Kobayashi R, Logothetis CJ, Yu-Lee LY, Lin SH. Aberrant expression of katanin p60 in prostate cancer bone metastasis. The Prostate. 72: 291-300. PMID 21681775 DOI: 10.1002/pros.21431 |
0.391 |
|
| 2011 |
Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Research. 71: 5194-203. PMID 21670081 DOI: 10.1158/0008-5472.Can-10-4374 |
0.422 |
|
| 2010 |
Tu SM, Lin SH, Podoloff DA, Logothetis CJ. Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clinical Advances in Hematology & Oncology : H&O. 8: 341-51. PMID 20551894 |
0.381 |
|
| 2010 |
Bawa-Khalfe T, Cheng J, Lin SH, Ittmann MM, Yeh ET. SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. The Journal of Biological Chemistry. 285: 25859-66. PMID 20551310 DOI: 10.1074/jbc.M110.134874 |
0.6 |
|
| 2010 |
Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB, Liu J. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3875-86. PMID 20505188 DOI: 10.1158/1078-0432.CCR-10-0483 |
0.311 |
|
| 2010 |
Huang CF, Lira C, Chu K, Bilen MA, Lee YC, Ye X, Kim SM, Ortiz A, Wu FL, Logothetis CJ, Yu-Lee LY, Lin SH. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Research. 70: 4580-9. PMID 20484040 DOI: 10.1158/0008-5472.CAN-09-3016 |
0.464 |
|
| 2010 |
Lee YC, Cheng CJ, Huang M, Bilen MA, Ye X, Navone NM, Chu K, Kao HH, Yu-Lee LY, Wang Z, Lin SH. Androgen depletion up-regulates cadherin-11 expression in prostate cancer. The Journal of Pathology. 221: 68-76. PMID 20191612 DOI: 10.1002/path.2687 |
0.587 |
|
| 2009 |
Zhang S, Wang J, Bilen MA, Lin SH, Stupp SI, Satcher RL. Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts. Clinical & Experimental Metastasis. 26: 993-1004. PMID 19787436 DOI: 10.1007/S10585-009-9289-0 |
0.439 |
|
| 2008 |
Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT, Yu-Lee LY, Zhang S, Yeh ET, Hu MC, Logothetis CJ, Lin SH. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Molecular Cancer Research : McR. 6: 1259-67. PMID 18708358 DOI: 10.1158/1541-7786.MCR-08-0077 |
0.549 |
|
| 2008 |
Lira CB, Chu K, Lee YC, Hu MC, Lin SH. Expression of the extracellular domain of OB-cadherin as an Fc fusion protein using bicistronic retroviral expression vector. Protein Expression and Purification. 61: 220-6. PMID 18620062 DOI: 10.1016/j.pep.2008.06.007 |
0.526 |
|
| 2008 |
Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, ... ... Lin SH, et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. The Journal of Clinical Investigation. 118: 2697-710. PMID 18618013 DOI: 10.1172/Jci33093 |
0.505 |
|
| 2008 |
Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3729-36. PMID 18559590 DOI: 10.1158/1078-0432.CCR-08-0472 |
0.35 |
|
| 2008 |
Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1599-602. PMID 18347159 DOI: 10.1158/1078-0432.CCR-07-4603 |
0.418 |
|
| 2008 |
Tu SM, Lin SH. Current trials using bone-targeting agents in prostate cancer. Cancer Journal (Sudbury, Mass.). 14: 35-9. PMID 18303481 DOI: 10.1097/PPO.0b013e318161d32d |
0.442 |
|
| 2007 |
Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, Lin SH. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Research. 67: 6544-8. PMID 17638862 DOI: 10.1158/0008-5472.Can-07-1330 |
0.518 |
|
| 2007 |
Cheng CJ, Ye XC, Vakar-Lopez F, Kim J, Tu SM, Chen DT, Navone NM, Yu-Lee LY, Lin SH, Hu MC. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Molecular Cancer Research : McR. 5: 675-84. PMID 17634423 DOI: 10.1158/1541-7786.MCR-06-0306 |
0.553 |
|
| 2007 |
Ye XC, Choueiri M, Tu SM, Lin SH. Biology and clinical management of prostate cancer bone metastasis. Frontiers in Bioscience : a Journal and Virtual Library. 12: 3273-86. PMID 17485298 |
0.489 |
|
| 2006 |
Choueiri MB, Tu SM, Yu-Lee LY, Lin SH. The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Reviews. 25: 601-9. PMID 17160554 DOI: 10.1007/s10555-006-9034-y |
0.381 |
|
| 2005 |
Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Long-term effects of strontium-89 combined with chemotherapy in patients with androgen-independent prostate cancer and bone metastases. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4671. PMID 27946829 DOI: 10.1200/jco.2005.23.16_suppl.4671 |
0.362 |
|
| 2005 |
Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7904-10. PMID 16258090 DOI: 10.1200/JCO.2005.01.2310 |
0.394 |
|
| 2005 |
Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H, Ittmann M, Tsai SY, Tsai MJ. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Research. 65: 7976-83. PMID 16140970 DOI: 10.1158/0008-5472.CAN-04-4076 |
0.585 |
|
| 2005 |
Liang AK, Liu J, Mao SA, Siu VS, Lee YC, Lin SH. Expression of recombinant MDA-BF-1 with a kinase recognition site and a 7-histidine tag for receptor binding and purification. Protein Expression and Purification. 44: 58-64. PMID 15914029 DOI: 10.1016/j.pep.2005.03.025 |
0.4 |
|
| 2005 |
Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nature Reviews. Cancer. 5: 21-8. PMID 15630412 DOI: 10.1038/nrc1528 |
0.412 |
|
| 2004 |
Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY, Lin SH. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. The Journal of Pathology. 203: 688-95. PMID 15141384 DOI: 10.1002/path.1568 |
0.33 |
|
| 2004 |
Phan D, Cheng CJ, Galfione M, Vakar-Lopez F, Tunstead J, Thompson NE, Burgess RR, Najjar SM, Yu-Lee LY, Lin SH. Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. Cancer Research. 64: 3072-8. PMID 15126343 DOI: 10.1158/0008-5472.Can-03-3730 |
0.552 |
|
| 2004 |
Tu SM, Lin SH. Clinical aspects of bone metastases in prostate cancer. Cancer Treatment and Research. 118: 23-46. PMID 15043187 |
0.441 |
|
| 2004 |
Lin SH, Nishino M, Luo W, Aumais JP, Galfione M, Kuang J, Yu-Lee LY. Inhibition of prostate tumor growth by overexpression of NudC, a microtubule motor-associated protein. Oncogene. 23: 2499-506. PMID 14676831 DOI: 10.1038/sj.onc.1207343 |
0.421 |
|
| 2003 |
Tu SM, Lin SH, Logothetis C. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute. 95: 1174-5; author reply. PMID 12902452 |
0.321 |
|
| 2003 |
Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Research. 63: 386-93. PMID 12543792 |
0.532 |
|
| 2002 |
Pu YS, Do KA, Luo W, Logothetis CJ, Lin SH. Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. Anti-Cancer Drugs. 13: 743-9. PMID 12187331 |
0.376 |
|
| 2002 |
Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer. 94: 2610-7. PMID 12173328 DOI: 10.1002/cncr.10546 |
0.428 |
|
| 2002 |
Volpert O, Luo W, Liu TJ, Estrera VT, Logothetis C, Lin SH. Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. The Journal of Biological Chemistry. 277: 35696-702. PMID 12122002 DOI: 10.1074/jbc.M205319200 |
0.49 |
|
| 2002 |
Chua SS, Ma ZQ, Gong L, Lin SH, DeMayo FJ, Tsai SY. Ectopic expression of FGF-3 results in abnormal prostate and Wolffian duct development. Oncogene. 21: 1899-908. PMID 11896623 DOI: 10.1038/sj.onc.1205096 |
0.553 |
|
| 2002 |
Phan D, Sui X, Chen DT, Najjar SM, Jenster G, Lin SH. Androgen regulation of the cell-cell adhesion molecule-1 (Ceacam1) gene. Molecular and Cellular Endocrinology. 184: 115-23. PMID 11694347 DOI: 10.1016/S0303-7207(01)00638-4 |
0.551 |
|
| 1999 |
Luo W, Tapolsky M, Earley K, Wood CG, Wilson DR, Logothetis CJ, Lin SH. Tumor-suppressive activity of CD66a in prostate cancer. Cancer Gene Therapy. 6: 313-21. PMID 10419049 DOI: 10.1038/sj.cgt.7700055 |
0.579 |
|
| 1999 |
Comegys MM, Carreiro MP, Brown JF, Mazzacua A, Flanagan DL, Makarovskiy A, Lin SH, Hixson DC. C-CAM1 expression: differential effects on morphology, differentiation state and suppression of human PC-3 prostate carcinoma cells. Oncogene. 18: 3261-76. PMID 10359532 DOI: 10.1038/Sj.Onc.1202666 |
0.454 |
|
| 1999 |
Makarovskiy AN, Pu YS, Lo P, Earley K, Paglia M, Hixson DC, Lin SH. Expression and androgen regulation of C-CAM cell adhesion molecule isoforms in rat dorsal and ventral prostate. Oncogene. 18: 3252-60. PMID 10359531 DOI: 10.1038/Sj.Onc.1202665 |
0.5 |
|
| 1998 |
Chen ME, Lin SH, Chung LW, Sikes RA. Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. The Journal of Biological Chemistry. 273: 17618-25. PMID 9651357 DOI: 10.1074/Jbc.273.28.17618 |
0.601 |
|
| 1998 |
Luo W, Earley K, Tantingco V, Hixson DC, Liang TC, Lin SH. Association of an 80 kDa protein with C-CAM1 cytoplasmic domain correlates with C-CAM1-mediated growth inhibition. Oncogene. 16: 1141-7. PMID 9528856 DOI: 10.1038/Sj.Onc.1201619 |
0.302 |
|
| Show low-probability matches. |